Investigating the Range of Symptom Endorsement at Initiation of a Graduated Return-to-Play Protocol After Concussion and Duration of the Protocol: A Study From the National Collegiate Athletic Association-Department of Defense Concussion, Assessment, Research, and Education (CARE) Consortium.


Journal

The American journal of sports medicine
ISSN: 1552-3365
Titre abrégé: Am J Sports Med
Pays: United States
ID NLM: 7609541

Informations de publication

Date de publication:
05 2020
Historique:
pubmed: 17 4 2020
medline: 9 10 2020
entrez: 17 4 2020
Statut: ppublish

Résumé

Organizations recommend that athletes should be asymptomatic or symptom-limited before initiating a graduated return-to-play (GRTP) protocol after sports-related concussion, although asymptomatic or symptom-limited is not well-defined. (1) There will be a range (ie, beyond zero as indicator of "symptom-free") in symptom severity endorsement when athletes are deemed ready to initiate a GRTP protocol. (2) Baseline symptom severity scores and demographic/preinjury medical history factors influence symptom severity scores at the commencement of the GRTP protocol. (3) Greater symptom severity scores at GRTP protocol initiation will result in longer protocol duration. (4) Symptom severity scores will not differ between those who did and did not sustain a repeat injury within 90 days of their initial injury. Cohort study; Level of evidence, 2. Across 30 universities, athletes (N = 1531) completed assessments at baseline and before beginning the GRTP protocol, as determined by local medical staff. Symptom severity scores were recorded with the symptom checklist of the Sport Concussion Assessment Tool-3rd Edition. Nonparametric comparisons were used to examine the effect of medical, demographic, and injury factors on symptom endorsement at GRTP protocol initiation, as well as differences in symptom severity scores between those who did and did not sustain a repeat injury within 90 days. A Cox regression was used to examine the association between symptom severity scores at GRTP protocol initiation and protocol duration. Symptom severity scores at the time when the GRTP protocol was initiated were as follows: 0 to 5 (n = 1378; 90.0%), 6 to 10 (n = 76; 5.0%), 11 to 20 (n = 42; 3.0%), and ≥21 (n = 35; 2.0%). Demographic (sex and age), medical (psychiatric disorders, attention-deficit/hyperactivity disorder, learning disorder), and other factors (baseline symptom endorsement and sleep) were significantly associated with higher symptom severity scores at the GRTP initiation ( A range of symptom severity endorsement was observed at GRTP protocol initiation, with higher endorsement among those with higher baseline symptom endorsement and select demographic and medical history factors. Findings suggest that initiation of a GRTP protocol before an absolute absence of all symptoms is not associated with longer progression of the GRTP protocol, although symptom severity scores >10 were associated with longer duration of a GRTP protocol. Results can be utilized to guide clinicians toward optimal GRTP initiation (ie, balancing active recovery with avoidance of premature return to activity).

Sections du résumé

BACKGROUND
Organizations recommend that athletes should be asymptomatic or symptom-limited before initiating a graduated return-to-play (GRTP) protocol after sports-related concussion, although asymptomatic or symptom-limited is not well-defined.
HYPOTHESES
(1) There will be a range (ie, beyond zero as indicator of "symptom-free") in symptom severity endorsement when athletes are deemed ready to initiate a GRTP protocol. (2) Baseline symptom severity scores and demographic/preinjury medical history factors influence symptom severity scores at the commencement of the GRTP protocol. (3) Greater symptom severity scores at GRTP protocol initiation will result in longer protocol duration. (4) Symptom severity scores will not differ between those who did and did not sustain a repeat injury within 90 days of their initial injury.
STUDY DESIGN
Cohort study; Level of evidence, 2.
METHODS
Across 30 universities, athletes (N = 1531) completed assessments at baseline and before beginning the GRTP protocol, as determined by local medical staff. Symptom severity scores were recorded with the symptom checklist of the Sport Concussion Assessment Tool-3rd Edition. Nonparametric comparisons were used to examine the effect of medical, demographic, and injury factors on symptom endorsement at GRTP protocol initiation, as well as differences in symptom severity scores between those who did and did not sustain a repeat injury within 90 days. A Cox regression was used to examine the association between symptom severity scores at GRTP protocol initiation and protocol duration.
RESULTS
Symptom severity scores at the time when the GRTP protocol was initiated were as follows: 0 to 5 (n = 1378; 90.0%), 6 to 10 (n = 76; 5.0%), 11 to 20 (n = 42; 3.0%), and ≥21 (n = 35; 2.0%). Demographic (sex and age), medical (psychiatric disorders, attention-deficit/hyperactivity disorder, learning disorder), and other factors (baseline symptom endorsement and sleep) were significantly associated with higher symptom severity scores at the GRTP initiation (
CONCLUSION
A range of symptom severity endorsement was observed at GRTP protocol initiation, with higher endorsement among those with higher baseline symptom endorsement and select demographic and medical history factors. Findings suggest that initiation of a GRTP protocol before an absolute absence of all symptoms is not associated with longer progression of the GRTP protocol, although symptom severity scores >10 were associated with longer duration of a GRTP protocol. Results can be utilized to guide clinicians toward optimal GRTP initiation (ie, balancing active recovery with avoidance of premature return to activity).

Identifiants

pubmed: 32298132
doi: 10.1177/0363546520913252
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1476-1484

Auteurs

Benjamin L Brett (BL)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Katherine Breedlove (K)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Thomas W McAllister (TW)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Steven P Broglio (SP)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Michael A McCrea (MA)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

April Marie Reed Hoy (AMR)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Joseph B Hazzard (JB)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Louise A Kelly (LA)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Nicholas Port (N)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Margot Putukian (M)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Paul Pasquina (P)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Jonathan Jackson (J)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Gerald McGinty (G)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Patrick O'Donnell (P)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Kenneth L Cameron (KL)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Megan N Houston (MN)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Christopher Giza (C)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Holly J Benjamin (HJ)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Thomas Buckley (T)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

James R Clugston (JR)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Julianne D Schmidt (JD)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Luis A Feigenbaum (LA)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Jason P Mihalik (JP)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Kevin Guskiewicz (K)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Scott Anderson (S)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Christina L Master (CL)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Michael W Collins (MW)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Anthony P Kontos (AP)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Sara P D Chrisman (SPD)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

M Alison Brooks (MA)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Steven Rowson (S)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Christopher M Miles (CM)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Adam Susmarski (A)

Investigation performed at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH